1 Min Read
* SPARK THERAPEUTICS CEO SAYS PLANS TO BEGIN PROGRAM IN POMPE DISEASE
* SPARK CEO SAYS EXPECTS LUXTURNA GENE THERAPY TO BE AVAILABLE TO PATIENTS IN EUROPE IN 2019 Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.